biosynthesis of the Avionins, a new class of lantibiotics

核糖体合成和翻译后修饰肽（RiPP）微维氨酸，从放线菌相关的细菌中分离出来，显示出有趣的抗菌特性。此外，它还具有一个新的结构基序组合，一个鸟氨酸（鸟酰半胱氨酸-阴唇氨酸）桥和一个n端双甲基化鸟苷脂肪酸。由于其有希望的性质，对其生物合成的深入研究（脂化镧肽）计划。这应该通过修饰和诱变生产生物体以及通过体外蛋白质生化测定来实现。因此，不仅研究了生物合成和对底物的需求，而且还在中间时间尺度上靶向生产具有改变生物活性的药物衍生物。此外，通过基因组挖掘，将鉴定出更多的脂肽生产者并检测到相应的化合物。因此，一组新的脂化ripp将被深入研究，并可能推动新的抗菌药物的开发。

The ribosomally synthesised and posttranslationally modified peptide (RiPP) microvionine, isolated from a bacterium related to Actinomycetes, shows interesting antibacterial properties. In addition, it has a new combination of structural motifs, an avionine (avionylcysteine-labionine)-bridge and an N-terminal, bismethylated guanidino fatty acid. Due to its promising properties a deeper investigation of its biosynthesis of this forst lipolanthine (lipidated lanthipeptide) is planned. This should be achieved by modification and mutagenesis of the producing organism as well as by in vitro by protein-biochemical assays. Hence, not only the biosynthesis and the requirements for substrates are investigated, but also on an intermediate time scale derivatives of the drug with altered bioactivity are targeted to be produced. Furthermore, by genome mining more lipolanthine-producers will be identified and the corresponding compounds detected. Hence, a new group of lipidated RiPPs will be studies in-depth and the development of new antimicrobial drugs may be pushed forward.